Dianthus Therapeutics (DNTH) Return on Capital Employed (2018 - 2025)
Dianthus Therapeutics (DNTH) recorded quarterly Return on Capital Employed of 32.79% in Q3 2025, up 19.94% quarter-over-quarter from 40.95% in Q2 2025, and down 882.0% on a YoY basis from 4.19% in Q3 2024.
Dianthus Therapeutics (DNTH) Return on Capital Employed (2018 - 2025) Analysis & Trends
Dianthus Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 32.79% for Q3 2025.
- In Q3 2025, Return on Capital Employed fell 882.0% year-over-year to 32.79%; the TTM figure through Sep 2025 stood at 32.79% (down 882.0% YoY), while the FY2024 annual figure was 39.44%, up 16.0% from the prior year.
- Return on Capital Employed was 32.79% for Q3 2025 at Dianthus Therapeutics, up from 40.95% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 18.8% in Q2 2024 to a low of 57.85% in Q1 2023.
- Historically, Return on Capital Employed has averaged 38.67% across 5 years, with a median of 39.89% in 2021.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 3640 bps in 2024, then plunged 2215 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 39.89% in 2021, then tumbled by 32 bps to 52.75% in 2022, then soared by 48 bps to 27.32% in 2023, then dropped by 8 bps to 29.47% in 2024, then retreated by 11 bps to 32.79% in 2025.
- The last three Return on Capital Employed figures came in at 32.79% (Q3 2025), 40.95% (Q2 2025), and 34.04% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -32.79% |
| Jun 30, 2025 | -40.95% |
| Mar 31, 2025 | -34.04% |
| Dec 31, 2024 | -29.47% |
| Sep 30, 2024 | -23.97% |
| Jun 30, 2024 | -18.80% |
| Mar 31, 2024 | -21.45% |
| Dec 31, 2023 | -27.32% |
| Sep 30, 2023 | -37.49% |
| Jun 30, 2023 | -49.87% |
| Mar 31, 2023 | -57.85% |
| Dec 31, 2022 | -52.75% |
| Sep 30, 2022 | -44.87% |
| Jun 30, 2022 | -46.28% |
| Mar 31, 2022 | -44.83% |
| Dec 31, 2021 | -39.89% |
| Sep 30, 2021 | -36.24% |
| Jun 30, 2021 | -43.03% |
| Mar 31, 2021 | -52.92% |
| Dec 31, 2020 | -50.22% |